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Abstract
Hypoxia is a central component of the tumor microenvironment and represents a major source of 
therapeutic failure in cancer therapy. Recent work has provided a wealth of evidence that 
noncoding RNAs and, in particular, microRNAs, are significant members of the adaptive response 
to low oxygen in tumors. All published studies agree that miR-210 specifically is a robust target of 
hypoxia-inducible factors, and the induction of miR-210 is a consistent characteristic of the 
hypoxic response in normal and transformed cells. Overexpression of miR-210 is detected in most 
solid tumors and has been linked to adverse prognosis in patients with soft-tissue sarcoma, breast, 
head and neck, and pancreatic cancer. A wide variety of miR-210 targets have been identified, 
pointing to roles in the cell cycle, mitochondrial oxidative metabolism, angiogenesis, DNA 
damage response, and cell survival. Additional microRNAs seem to be modulated by low oxygen 
in a more tissue-specific fashion, adding another layer of complexity to the vast array of protein-
coding genes regulated by hypoxia.
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10.1 Introduction
Tissue hypoxia is a dynamic feature of virtually all solid tumors (Semenza 2010a). The 
adaptive response to low oxygen encompasses complex biochemical and cellular processes, 
such as energy metabolism, cell survival and proliferation, angiogenesis, adhesion, and 
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motility (Ruan et al. 2009). These, in turn, shape the natural history of cancer and constitute 
a major source of therapeutic failure in oncology (Brown and Giaccia 1998). During the past 
two decades, clinical research and animal models have provided strong evidence that tumors 
with extensive low oxygen tension are more likely exhibit poor prognosis (Vaupel and 
Mayer 2007). Therefore, a deep understanding of cellular adaptation to oxygen deprivation 
is key for developing more efficient therapeutic strategies (Wilson and Hay 2011).
Cells react to hypoxia in part via a transcriptional program orchestrated by an oxygen-
monitoring machinery that is centered around the hypoxia-inducible factors (HIFs) (Wang 
and Semenza 1993; Wang et al. 1995; Wang and Semenza 1995). HIFs are heterodimers 
consisting of an oxygen-sensitive α-subunit (HIFα) and a constitutively expressed β-subunit 
(HIF1β, also called aryl hydrocarbon receptor nuclear translocator). Among the three 
homologous HIFα genes, HIF-1α, HIF-2α, and HIF-3α, the functions of HIF-1α and 
HIF-2α are best characterized. Under normoxic conditions, HIFα is hydroxylated by 
prolyl-4-hydroxylases, targeting it for proteasomal destruction mediated by the von Hippel-
Lindau (VHL) protein-containing E3 ubiquitin ligase (Ivan et al. 2001; Jaakkola et al. 2001). 
When oxygen becomes limiting, decreased prolyl-4-hydroxylase activity leads to HIFα 
stabilization and heterodimerization with the β-subunit, followed by translocation to the 
nucleus and activation of hundreds of target genes (Semenza 2012). The protein-coding 
components of the HIF-mediated response are discussed in detail elsewhere in this book.
10.2 Noncoding RNA: Wide Roles in Physiology and Pathology
While protein coding sequences account for only approximately 1.1 % of the entire human 
genome (Venter et al. 2001), during the past decade it has become apparent that the vast 
majority of the noncoding sequences are, in fact, actively transcribed (Djebali et al. 2012). 
Given the long history of evolution that has shaped the human genome, it is unlikely that 
these transcripts are results of “background transcriptional noise.” During the past decade, 
largely because of rapid advancements in microarray and next-generation sequencing 
technologies, the “dark matter” of the human genome has been found to encode tens of 
thousands of noncoding RNAs (ncRNAs). This is a highly heterogeneous superfamily, 
including diverse entities such as ribosomal RNAs, small nucleolar RNAs, small nuclear 
RNAs, transfer RNA, small interfering RNAs, piwi-associated RNAs, microRNA (miRNA), 
unusually small RNA, and long ncRNAs. Despite failing to be translated into proteins, it 
already has been demonstrated that a small percentage of ncRNAs exhibit important 
biological functions, and many more are suspected to do so (Hüttenhofer et al. 2005). By far 
the best-characterized ncRNAs, both in general as well as in the particular context of 
hypoxia, are miRNAs, which are the main focus of this chapter.
10.2.1 MicroRNAs
miRNAs are single-stranded, small ncRNA molecules (~22 nucleotides in length) that 
regulate gene expression by inhibiting messenger RNA (mRNA) translation or by 
facilitating cleavage of the target mRNA (Valencia-Sanchez et al. 2006). Our understanding 
of miRNA biology was relatively slow to emerge. The first miRNA, lin-4, was discovered in 
Caenorhabditis elegans in 1993 (Lee et al. 1993; Wightman et al. 1993), followed by the 
second miRNA, let-7, 7 years later (Reinhart et al. 2000). The finding that let-7 is well 
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conserved in a wide range of animal species (Pasquinelli et al. 2000) spurred an accelerated 
expansion of miRNA discovery that is still ongoing. To date more than 2,200 miRNAs have 
been identified in the human genome (miRBase Release 19, http://www.mirbase.org), and at 
least one-third of all protein-encoding genes are now predicted to be regulated by miRNAs 
(Lewis et al. 2005). miRNAs are widely recognized as important regulators in 
developmental, physiological, and pathological settings, including cell growth, 
differentiation, metabolism, viral infection, and tumorigenesis (Bushati and Cohen 2007). In 
fact, one would be hard pressed to name a biomedical field that has not been affected in one 
way or another by miRNA research.
Genes encoding miRNAs are initially transcribed by RNA polymerase II as part of much 
longer primary transcripts (pri-miRNAs) (Lee et al. 2002) that typically contain the cap 
structure and the poly(A) tails (Lee et al. 2004). This feature predicts the presence of a 
wealth of pri-miRNAs alongside mRNA in most whole transcriptome databases. In the 
second step, pri-miRNAs are processed by the nuclear RNase III Drosha, leading to ~70 
nucleotide hairpin-shaped intermediates, called precursor miRNAs (pre-miRNAs). Pre-
miRNAs are subsequently exported out of the nucleus and cleaved by the cytoplasmic 
RNase III Dicer into a short miRNA duplex. One strand of this short-lived duplex is 
degraded, while the other strand is retained as mature miRNA and incorporated into the 
RNA-induced silencing complex (RISC), an RNA-protein complex with proteins from the 
Argonaute family (Schwarz et al. 2003).
The mature miRNA guides the RISC to recognize its target mRNA based on sequence 
complementarity, most important between the “seed region” of mature miRNAs, nucleotides 
2–8, and the 3′ untranslated regions (UTRs) of their target genes, which generally leads to 
translation inhibition and/or mRNA degradation (Djuranovic et al. 2011, 2012). Because a 
perfect sequence complementarity is usually only required between the seed region of a 
miRNA and the 3′ UTR of its target mRNA, a single miRNA can theoretically regulate 
multiple mRNAs (often hundreds) (Fig. 10.1). Conversely, the 3′ UTR of a given mRNA 
may contain several miRNA recognition sequences. This relative lack of specificity poses 
significant challenges for the miRNA research field, in particular in identifying biologically 
meaningful miRNA targets.
While highly meaningful for normal cell function, miRNAs have been investigated in depth 
in most pathological settings, with cancer arguably leading the way. Deregulated miRNA 
expression has been demonstrated in virtually all neoplasms investigated. It is interesting to 
note that different cancer types tend to exhibit specific miRNA signatures (Lu et al. 2005; 
Calin and Croce 2006), including cancers of the colon (Michael et al. 2003), breast (Iorio et 
al. 2005), brain (Ciafre et al. 2005), liver (Murakami et al. 2006), and lung (Yanaihara et al. 
2006). Although the elucidation of the mechanisms behind the specific shifts of profiles in 
tumors remains a work in progress, recent data on miRNA responses to microenvironmental 
stresses and oncogenic alterations have provided critical clues.
During the past 6 years multiple reports have demonstrated that miRNAs are involved in the 
hypoxic response and contribute to the repression of specific genes under low oxygen 
conditions (Donker et al. 2007; Kulshreshtha et al. 2007a; Camps et al. 2008; Fasanaro et al. 
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2008; Giannakakis et al. 2008; Huang et al. 2009; Gee et al. 2010). The next section 
summarizes the current knowledge about the involvement of miRNAs in cellular hypoxic 
response, discusses challenges for elucidation of their biological functions, and speculates 
on potential opportunities for cancer diagnosis, prognosis, and treatment.
10.3 Hypoxia-Regulated miRNAs: The New Paradigm of Cellular Response 
to a Hypoxic Microenvironment
Several groups from diverse fields embarked on genome-wide miRNA profiling, with the 
goal to identify hypoxia-regulated miRNAs in a variety of cellular contexts. Expression of 
several dozen mature miRNAs, including miR-210, -21, -23, -24, -26, -103/107, and -181, 
was found to be induced under hypoxic conditions (Kulshreshtha et al. 2007b; Camps et al. 
2008; Fasanaro et al. 2008; Crosby et al. 2009; Huang et al. 2009; Sarkar et al. 2010; Chen 
et al. 2012). Although these miRNA were reported in at least two publications, relatively 
limited overall overlap was noticed among these studies. With the caveat that different 
technologies were employed by different groups, this variability suggests a cell-specific 
component of miRNA induction and maturation. This in turn may contribute to the well-
recognized variations in the magnitude of coding gene responses in hypoxia. Moreover, a 
large number of mature miRNAs were found to be downregulated in hypoxia (Kulshreshtha 
et al. 2007a), and their role may be to de-repress expression of specific genes in low oxygen 
conditions.
In sharp contrast, hypoxic-induced miR-210 stands out as the only miRNA agreed on by all 
the studies to date (Huang et al. 2010). This is drastically different from the case of classic 
protein-coding genes in which a plethora of mRNAs with diverse functions are induced by 
hypoxia, with relatively good overlap between different cell types (Denko et al. 2003). 
According to most groups that investigated the hypoxic regulation of miR-210, it seems to 
be a rather specific HIF-1 target (Camps et al. 2008; Crosby et al. 2009; Huang et al. 2009; 
Kim et al. 2009). However, this specificity is not absolute because HIF-2-dependent 
regulation of miR-210 also has been reported (Zhang et al. 2009). As is the case for the 
classic genes, HIF-1 directly binds to a hypoxia-responsive element (HRE) on the proximal 
miR-210 promoter (Huang et al. 2009). When the miR-210 core promoter is compared 
across species, this HRE site is highly conserved, indicating the importance of hypoxia/HIFs 
in regulating miR-210 expression during evolution. Consistent with this observation, the 
induction of mouse miR-210 under hypoxia is dependent on HIF-1α (Crosby et al. 2009). 
This highly conserved HRE was recently confirmed to be the functional HRE that is 
responsible for the robust induction of mouse miR-210 expression under hypoxic conditions 
(Cicchillitti et al. 2012).
10.3.1 miR-210: A Mirror of HIF Activity with Clinical Implications
miR-210 is upregulated in most solid tumors investigated to date, and its levels generally 
correlate with a negative clinical outcome (Kulshreshtha et al. 2007b; Porkka et al. 2007; 
Zhang et al. 2007; Fasanaro et al. 2008; Foekens et al. 2008; Lawrie et al. 2008; Gee et al. 
2010; Rothe et al. 2011; Hong et al. 2012). Moreover, miR-210 levels are correlated with a 
gene expression signature of hypoxia (Camps et al. 2008; Huang et al. 2009), suggesting that 
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its overexpression in tumors is the direct consequence of decreased oxygen tension in the 
microenvironment. In addition to tissue expression, in our laboratory, we observed a 
significant increase of circulating miR-210 in patients with pancreatic cancer compared to 
healthy controls (Ho et al. 2010). This is consistent with our knowledge of miR-210’s 
responsiveness to hypoxia, since pancreatic adenocarcinomas are usually highly hypoxic 
(Koong et al. 2000).
Whether miR-210 independently increases tumor aggressiveness and/or decreases the 
response to therapy is still a matter of debate, although there is preliminary evidence to 
suggest such an effect (Camps et al. 2008). An emerging paradigm is that miR-210 
expression is an accurate readout of HIF-1 activity in vivo, as it is in vitro (Fasanaro et al. 
2008; Huang et al. 2009; Devlin et al. 2011).
One particular disease that is connected closely with the HIF pathway is clear-cell renal cell 
carcinomas (ccRCCs), which is commonly associated with the inactivation of the VHL 
tumor suppressor gene (Presti et al. 1991; Brugarolas 2007). Mutations and loss of 
heterozygosity of the VHL gene have been found in 57 % and 98 % of sporadic renal cell 
carcinoma cases, respectively (Gnarra et al. 1994). The VHL tumor suppressor gene product 
functions as the adaptor subunit of the E3 ubiquitin ligase complex that targets hydroxylated 
HIF-1α and HIF-2α for ubiquitination and subsequent degradation by the 26S proteasome 
(Ivan et al. 2001; Jaakkola et al. 2001). Given its close relationship with HIF, it is not 
surprising that miR-210 is particularly overexpressed in ccRCCs (Juan et al. 2010; White et 
al. 2011; Redova et al. 2012). In addition, elevated levels of circulating miR-210 have been 
found in patients with ccRCC compared to healthy controls (Zhao et al. 2013). Although the 
origin of circulating miRNAs remains a much-debated subject, the existence of high-level 
miR-210 in circulation in these patients suggests that miR-210 may serve as a novel 
biomarker for noninvasive detection of highly hypoxic cancers.
While our own work has focused on the emerging roles of miR-210 in tumors, the impact of 
this miRNA most likely extends well beyond cancer biology, most notably in cardiac 
cerebrovascular diseases (Semenza 2010b), cardiac hypertrophy and failure (van Rooij et al. 
2006; Thum et al. 2007; Greco et al. 2012), transient focal brain ischemia (Jeyaseelan et al. 
2008), limb ischemia (Jeyaseelan et al. 2008; Pulkkinen et al. 2008), ischemic wounds 
(Biswas et al. 2010), acute myocardial infarction (Bostjancic et al. 2009), atherosclerosis 
obliterans (Li et al. 2011), and preeclampsia (Pineles et al. 2007; Zhu et al. 2009; 
Enquobahrie et al. 2011).
10.3.2 miR-210 Targets: A Growing and Diverse List
Identification of biologically relevant targets is an essential step toward understanding the 
functions of miR-210. A frequently employed approach begins with computational 
prediction using a growing number of programs available online. These are based on 
algorithms that search for complementarity between 3′ UTR sequences of annotated coding 
genes and the seed region sequence of the miRNA (Bartel 2009). Among the most popular 
programs employed to this end are miRanda (Betel et al. 2008), TargetScan (Lewis et al. 
2003), Pictar (Krek et al. 2005), PITA (Kertesz et al. 2007), MicroCosm (Griffiths-Jones et 
al. 2008), and Dianalab (Maragkakis et al. 2009). Drawing the line after several years of 
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experience with these resources, none stands out as the most accurate predictor of real 
targets. To further complicate matters, the lists of candidates generated by these programs 
usually exhibit limited overlap. This seems to be generally true for most miRNAs 
investigated and is exemplified by a proteomic study comparing the accuracy of different 
computational predictions of miR-223 targets (Baek et al. 2008). Since the miRNA seed 
region only consists of 6 or 7? nucleotides, false-positive prediction is a major limitation of 
this approach. Any given miRNA, including miR-210, may be predicted to regulate 
hundreds, if not thousands, of coding genes. When the search is extended to the 5′ UTR and 
the coding region, the number of targets is expected to be even higher. Finally, Fasanaro et 
al. (2012) have provided recent experimental evidence for a “seedless” target of miR-210 on 
the basis of complementarity between sequences of the ROD1 (regulator of differentiation 1) 
gene and 10 consecutive bases in the central portion of miR-210. It is interesting that two 
widely employed algorithms, PicTar and TargetScan, predict relatively few targets for 
human miR-210, and, conversely, most of the experimentally validated targets are not 
predicted by any of these programs with a high score. It is also becoming increasingly 
apparent that “seed” binding is not always sufficient, as other features of the surrounding 
sequences can affect binding efficacy (Lewis et al. 2005). In conclusion, while 
computational predictions still represent powerful tools in the search for targets, they suffer 
from clear limitations, and exclusive reliance on them can lead to long lists of limited use.
In the particular case of miR-210, a number of genes appearing on these lists have been 
confirmed, but the success was largely due to the addition of a strong experimental arm. 
Such confirmed target genes are involved in cell proliferation, mitochondrial metabolism, 
DNA repair, chromatin remodeling, and cell migration (Camps et al. 2008; Fasanaro et al. 
2008; Giannakakis et al. 2008; Pulkkinen et al. 2008; Chan et al. 2009; Crosby et al. 2009; 
Mizuno et al. 2009; Chen et al. 2010; Qin et al. 2010).
A widely used approach for identification of miRNA targets is a combination of expression 
profiling following miRNA manipulation using mimics and antagomirs, followed by 
expression profiling and comparisons with the results of computational predictions. This is a 
feasible strategy because directing mRNA degradation is a major mechanism that miRNAs 
use to downregulate the corresponding target genes (Lim et al. 2005; Guo et al. 2010). This 
effect is usually robust enough to be detected by microarray analysis or whole transcriptome 
RNA sequencing (RNA-Seq). For example, both Zhang et al. (2009) and Puissegur et al. 
(2011) began their search by identifying transcripts that were down-modulated upon forced 
miR-210 expression in colorectal and lung adenocarcinoma cancer cell lines, respectively. 
The downregulated genes, which also contained a predicted miR-210 binding site, were 
analyzed further to confirm that MNT (Zhang et al. 2009), NDUFA4, and SDHD (Puissegur 
et al. 2011) are bona fide miR-210 targets.
However, because miRNA frequently regulates its target gene by inhibiting protein 
translation rather than altering mRNA abundance (Selbach et al. 2008), complete reliance on 
mRNA profiling is likely to miss authentic miRNA targets. An ideal sensitive and robust 
proteomic approach should identify miRNA targets directly when combined with 
computational prediction. However, lack of sufficient sensitivity, heavy bias for abundant 
proteins, and high costs still preclude the broader application of this promising technology.
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A recent approach has emerged that, at least in part, allows us to overcome the above-
mentioned limitations. miRNAs is known to recruit the mRNAs of their target genes to the 
RISC complex, of which Argonaute family proteins, especially Argonaute 2, are essential 
components (Kawamata and Tomari 2010). Argonaute protein immunoprecipitation 
(miRNP-IP) methods have been developed that capture the mRNAs recruited to the 
complex. This pull-down can be followed by microarray or RNA-Seq and help identify 
targets that are regulated by both translational blockade or message degradation (Karginov 
et al. 2007). miRNP-IP can “freeze miRNAs in action” and thus greatly reduce the number 
of nonspecific targets and the secondary effect that are commonly seen in other approaches. 
Our groups have successfully pursued this approach in cells overexpressing miR-210 as part 
of more integrative strategies to identify targets (Fasanaro et al. 2009; Huang et al. 2009). In 
one of the studies we used a combination of computational prediction, proteomic, 
transcriptomic, and miRNP-IP approaches in human umbilical vein endothelial cells 
overexpressing miR-210 (Fasanaro et al. 2009). Proteomic profiling identified 11 
downregulated proteins, whereas transcriptome profiling identified 51 transcripts that are 
induced upon miR-210 knockdown and downregulated by miR-210 overexpression. Despite 
the fact that 42 of the 62 genes were enriched with miR-210 seed-complementary sequences 
in their 3′ UTRs, surprisingly few were predicted by the miRNA target identification 
algorithms listed above. To distinguish between direct and indirect targets, analysis of the 
miRNP-IP content was analyzed by quantitative reverse transcriptase polymerase chain 
reaction, revealing that 16 potential targets were enriched in the RISC. An ncRNA (XIST) 
involved in X chromosome inactivation was identified in the miRNP-IP experiment, 
indicating a previously unsuspected layer of interaction between ncRNAs. This finding 
lends support to the recently proposed competing endogenous RNA theory (Salmena et al. 
2011).
Using a similar miRNP-IP strategy, we also compared mRNAs enriched in the RISC after 
exposing immortalized human breast MCF10A cells to low oxygen for 24 hours? versus 
normoxic controls (Huang et al. 2009). More than 200 mRNAs were enriched, and several 
algorithms predicted that 50 of these were direct miR-210 targets. Three of five randomly 
selected genes from the list of 50 genes were confirmed as bona fide miR-210 targets by 
functional assays.
It is notable that there are few targets in common between these two studies, leading to the 
hypothesis that miR-210 regulates different sets of target genes in these two cell types. This 
is not necessarily surprising: comprehensive proteomic studies indicated that miRNAs act as 
rheostats by performing fine-scale adjustments to the output of hundreds of proteins (Baek et 
al. 2008; Selbach et al. 2008). Thus, only minor changes at the protein and/or mRNA levels 
are expected for the majority of miRNA targets, which translate into low fold changes (e.g., 
1.2–1.5) in target expression when measured by microarray or RNA-Seq. This inherent 
variability of our experimental systems to measure such small changes may account at least 
in part for the discrepancy between our studies.
The current paradigm of miRNA function states that they suppress target gene expression 
via inhibiting protein translation, degrading mRNA, or both (Bartel 2004). Several reports 
have provided the first evidence for exceptions to this rule, identifying genes that are 
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upregulated by miRNA transduction (Vasudevan et al. 2007; Place et al. 2008). Although no 
direct evidence for this has been provided for miR-210, upregulated gene expression was 
observed in our study (Fasanaro et al. 2009). At this point there is no evidence that this 
represents more than secondary waves of regulation.
We anticipate that improved understanding of miRNA function will be followed by the 
increased accuracy of predicting miRNA targets. Moreover, with the lowering cost of next-
generation sequencing, the combination of computational tools and advanced experimental 
approaches will provide a more complete identification of physiologically relevant miR-210 
targets. Figure 10.2 summarizes experimentally validated miR-210 targets and their 
potential regulatory functions. Some of the better-validated miR-210 targets are reviewed 
below, and their function in hypoxic response and cancer biology are discussed.
10.3.3 miR-210 Regulates Mitochondrial Metabolism and Oxidative Stress
Under normoxic conditions, mitochondria are the “energy factories” of a cell; they generate 
the majority of adenosine triphosphate through the oxidative phosphorylation pathway using 
oxygen as an electron acceptor. However, when the oxygen supply is limited, cells switch to 
glycolysis to produce adenosine triphosphate (the Pasteur effect). During this process, HIF-1 
not only upregulates expression of most glycolytic enzymes but also downregulates 
mitochondrial respiration and biogenesis (Zhang et al. 2007; Denko 2008). Results from 
several groups have demonstrated that hypoxic induction of miR-210 significantly 
contributes to this metabolic shift by downregulating the activity of mitochondrial electron 
transport chains (ETCs). A well-accepted branch of this mechanism is targeting by miR-210 
of the iron-sulfur cluster scaffold proteins (ISCU) (Chan et al. 2009; Fasanaro et al. 2009; 
Chen et al. 2010; Favaro et al. 2010). One of the most consistent miR-210 targets, ISCU is 
part of an ancient mechanism that catalyzes the assembly of iron-sulfur clusters that are 
critical for enzymes, such as aconitase, that function in the tricarboxylic acid cycle, as well 
as for the function of mitochondrial ETC complexes I, II, and III (Tong and Rouault 2006). 
The role of ISCU as a metabolic regulator has strong backing from clinical data: its 
mutations are associated with hereditary lactic acidosis characterized by myopathy and 
exercise intolerance (Mochel et al. 2008).
Further strengthening the case for ISCU as a biologically relevant target, its levels are 
inversely correlated with miR-210 in multiple tumor data sets (Favaro et al. 2010). In 
contrast to a poor prognosis predicted by higher levels of miR-210, the expression of ISCU 
is predictive of a favorable prognosis, at least in breast cancer, indicating that ISCU is 
regulated by miR-210 in vivo.
While ISCU itself is not a primarily mitochondrial protein, several integral components of 
the mitochondrial ETC have been found to be miR-210 targets: NADH dehydrogenase 
(ubiquinone) 1α subcomplex 4 (NDUFA4) (Giannakakis et al. 2008), succinate 
dehydrogenase complex, subunit D (SDHD) (Puissegur et al. 2011), and cytochrome C 
oxidase assembly homolog 10 (COX10) (Chen et al. 2010). NDUFA4 was initially 
considered to be part of ETC complex I until recent work demonstrated that it actually 
resides in complex IV (Balsa et al. 2012). SDHD is a subunit of complex II and a well-
documented tumor suppressor gene product (Baysal et al. 2000; Gottlieb and Tomlinson 
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2005). Targeting of this gene by miR-210 provides additional support to a protumorigenic 
role for miR-210. COX10, which encodes a heme A:farnesyltransferase, is another recently 
discovered target of miR-210. Although COX10 is not a structural subunit of COX 
(mitochondrial ETC complex IV), it is required for the expression of a functional COX 
complex (Antonicka et al. 2003). To summarize, by targeting multiple ETC components and 
regulators, miR-210 may act as a key HIF-1 effector in attenuating oxygen consumption in 
hypoxia. One unanswered question is whether miR-210 plays biological roles in anoxia, 
where decreasing oxygen consumption is not a factor.
Another intriguing target predicted by several programs and experimentally confirmed is 
glycerol-3-phosphate dehydrogenase 1-like (GPD1L) (Fasanaro et al. 2009). GPD1L is 
highly homologous to glycerol-3-phosphate dehydrogenases that transfer electrons from 
cytoplasmic NADH to the mitochondrial ETC (Bunoust et al. 2005). Thus, GPD1L may also 
be involved in the Pasteur effect by regulating NAD+-to-NADH ratios (Liu et al. 2010). 
Recent insights from Kelly et al. (2011) identified a feedback mechanism based on GPD1L 
repression, which in turn inactivates HIF prolyl hydroxylase activity, leading to stabilization 
of HIF-1α. Therefore, miR-210 may be present in or at both downstream and upstream of 
HIF-1α signaling. Puissegur et al. (2011) also showed that high levels of miR-210 
participate to stabilize HIF-1α during hypoxia.
The generation of mitochondrial reactive oxygen species (ROS) is a consequence of electron 
leakage during electron transport (Murphy 2009). Increased ROS production has been 
reported in hypoxia, potentially as a result of ETC dysfunction (Guzy and Schumacker 
2006); however, whether cell reoxygenation during the ROS assay contributes to this 
increase is still being debated. We reported that miR-210 increases oxidative stress at least 
in part by ISCU suppression in normoxic MCF7 cells (Chan et al. 2009; Favaro et al. 2010). 
However, in hypoxia, and in other cell types, the effects of miR-210 are still a subject of 
controversy. We observed hypoxic induction of ROS in cancer cell lines, and an miR-210 
antagonist reversed this effect to almost normoxic levels (Favaro et al. 2010). Conversely, 
Chan et al. (2009), working on endothelial cells, did not detect any change in ROS 
production after exposing the cells to hypoxia and noted a burst of ROS when miR-210 was 
blocked. This discrepancy is sure to promote additional investigation and may reflect 
underlying differences between normal versus cancer cells. In addition, miR-210 may 
exhibit differential effects on various ROS species, a hypothesis that needs to be addressed 
in future studies.
Aside from its robust response to oxygen deprivation, the HIF pathway plays an increasingly 
clear role in the Warburg effect (Kim and Dang 2006). HIF is also induced in tumors as part 
of oncogenic signaling networks, even in the absence of hypoxia (Zundel et al. 2000), so it is 
tempting to speculate that elevated miR-210 may contribute to the Warburg effect in these 
tumors by helping to stabilize HIF-1α to promote aerobic glycolysis. Expression of miR-210 
is frequently elevated in cancers, including glioblastomas (Malzkorn et al. 2009), 
melanomas (Satzger et al. 2009; Zhang et al. 2009), ccRCCs (Juan et al. 2010; White et al. 
2011), lung (Miko et al. 2009; Raponi et al. 2009), pancreatic cancers (Greither et al. 2009), 
and breast cancers (Camps et al. 2008; Foekens et al. 2008). However, whether elevated 
miR-210 expression within the tumor can occur outside of the hypoxic areas remains unclear 
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at this stage, and future laser-capture, microdissection-based analyses may shed critical light 
on this dilemma.
10.3.4 miR-210 as a Regulator of Angiogenesis
Angiogenesis is a complex, multistep process that normally occurs during embryonic 
development and rarely in adults. Exceptions include normal repair processes such as wound 
healing and pathological settings such as in tumor growth and ischemic disorders (Semenza 
2003). Tumor growth is highly dependent on the formation of neovessels to establish 
nutrient and oxygen supplies for cell viability and proliferation. Imbalance between oxygen 
consumption by tumor cells with high metabolic activities (Gatenby and Gillies 2004) and 
oxygen delivery by dysfunctional vasculature (Brown and Giaccia 1998) leads to hypoxia 
and stimulates compensatory angiogenesis (Liu et al. 1995).
Multiple miRNAs seem to be part of the various steps of the angiogenic response, either as 
positive or negative regulators (Wang and Olson 2009; Wu et al. 2009). On the basis of its 
involvement in the hypoxic response, it is hardly surprising that miR-210 has been 
investigated as a candidate angiogenic regulator. Consistent with this hypothesis, miR-210 
expression was found to correlate closely with vascular endothelial growth factor (VEGF) 
expression, hypoxia, and angiogenesis in patients with breast cancer (Foekens et al. 2008). 
Transduction of miR-210 in human umbilical vein endothelial cells using miRNA mimics 
functionally stimulates the formation of capillary-like structures as well as VEGF-induced 
cell migration (Fasanaro et al. 2008; Lou et al. 2012). Conversely, inhibiting miR-210 using 
the corresponding antagomir blocks both tubulogenesis and VEGF-mediated endothelial 
chemotaxis. The receptor tyrosine kinase ligand Ephrin-A3 (EFNA3) was identified as a 
candidate mediator for these effects (Fasanaro et al. 2008), consistent with the knowledge 
that ephrin ligands and their receptors are important in the development of the 
cardiovascular system and in vascular remodeling (Kuijper et al. 2007). Overall, EFNA3 
seems to be one of the most consistently reported miR-210 target genes (Fasanaro et al. 
2008; Fasanaro et al. 2009; Greither et al. 2009; Huang et al. 2009). To complicate matters, 
regulation of EFNA3 is more complex when ischemic responses are examined (Pulkkinen et 
al. 2008). Contrary to the expectation of miR210-mediated repression, EFNA3 was present 
at higher levels in mouse hippocampus after ischemia. It is interesting that EFNA3 
transcription is also induced by hypoxia (Fasanaro et al. 2008), suggesting that miR-210 
fine-tunes primarily EFNA3 protein translation. Thus, abundance of the EFNA3 protein may 
reflect the balance between hypoxic induction of mRNA and repression of miR-210, which 
conceivably varies in different pathological contexts.
The tyrosine phosphatase PTP1B was identified as another miR-210 target that promotes 
angiogenesis and inhibits apoptosis after myocardial infarction in a mouse model (Hu et al. 
2010). PTP1B is documented to negatively regulate activation of the VEGF receptor 2 and 
stabilize cell-cell adhesions through reducing tyrosine phosphorylation of vascular 
endothelial cadherin (Nakamura et al. 2008). Thus, by inhibiting EFNA3 and PTP1B, both 
negative regulators of angiogenesis, miR-210 could promote angiogenesis.
An interesting recent study also suggests positive feedback between VEGF and miR-210. 
CD34+ cells in umbilical cord blood expanded in VEGF-containing medium upregulated 
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miR-210 expression, and when these cells were transplanted into the ischemic hind limbs of 
mice tissue perfusion/capillary density were significantly improved, whereas an miR-210 
inhibitor abolished the effect (Alaiti et al. 2012).
While the above-mentioned studies were not conducted in the context of cancer, they may 
nevertheless shed new light on possible roles of miR-210 in tumor angiogenesis. It will be of 
great interest to investigate whether feedback involving hypoxia, miR-210, and VEGF also 
occurs in tumors in vivo. This may have implications for developing strategies to increase 
the efficacy of anti-VEGF therapy, for example, by adding miR-210 inhibitors.
10.3.5 miR-210 Regulation of DNA Damage Response
Genome integrity is challenged by a variety of stresses, including radiation, mutagens, ROS, 
ultraviolet light, and chemo-or radiotherapeutic agents. Cellular responses to DNA damage 
involve a complex network of processes that detect and repair genomic lesions. miRNAs 
have been demonstrated to participate in these processes (Simone et al. 2009; Landau and 
Slack 2011; Wan et al. 2011). Zhang et al. (2011) provided direct evidence that more than 
20 % of examined miRNAs are significantly induced upon DNA damage. While it is not 
robustly induced by irradiation, miR-210 nevertheless seems to be relevant for this complex 
process because it targets RAD52 (Crosby et al. 2009; Fasanaro et al. 2009), a key 
component in the homologous recombination–mediated repair of double-strand breaks 
(Benson et al. 1998; Shinohara and Ogawa 1998). Suppression of RAD52 by miR-210 may 
provide an additional mechanism to help explain compromised homologous recombination 
repair activity in hypoxic cells (Bindra et al. 2007). Consistent with this hypothesis, forced 
expression of miR-210 was found to lead to double-strand DNA breaks in cultured cells 
(Faraonio et al. 2012).
10.3.6 miR-210 Regulation of Apoptosis
Cellular stresses, including hypoxia, are well known triggers of programmed cells death, a 
process also called apoptosis. Evasion from apoptotic responses is critical for tumor 
progression: transformed cells need to overcome the adverse conditions present in their 
microenvironment (Hanahan and Weinberg 2011). Thus, it is not surprising that miR-210 
has been investigated for possible effects on apoptotic responses. In general, the available 
evidence suggests an anti-apoptotic role of miR-210 in a variety of cell types. On the one 
hand, overexpression of miR-210 can protect cells from apoptosis (Kulshreshtha et al. 
2007a; Kim et al. 2009; Hu et al. 2010; Mutharasan et al. 2011; Nie et al. 2011); on the other 
hand, downregulation of miR-210 during hypoxia promotes apoptosis (Cheng et al. 2005; 
Kulshreshtha et al. 2007b; Fasanaro et al. 2008; Gou et al. 2012; Liu et al. 2012; Yang et al. 
2012). While many gaps remain in our understanding of this process, several relevant targets 
have been identified to help explain such effect: E2F3 (Gou et al. 2012), Ptp1b (Hu et al. 
2010), caspase-8-associated protein-2 (CASP8AP2) (Kim et al. 2009), and apoptosis-
inducing factor, mitochondrion-associated 3 (AIFM3) (Yang et al. 2012). However, the 
caveat is that, apart from CASP8AP2 (Kim et al. 2012), none of the other genes has been 
verified to mediate miR-210’s anti-apoptotic function by an independent study. In a recent 
report, although AIFM3 was found to be an miR-210 target, its overexpression failed to 
overcome the cytoprotective effects of the miRNA, suggesting that cooperation with other 
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targets may be necessary (Mutharasan et al. 2011). Despite the evidence of an anti-apoptotic 
role cited above, a recent report suggested that miR-210 may also exhibit a pro-apoptotic 
function, at least in hypoxic neuroblastoma cells, by targeting the anti-apoptotic gene BCL2 
(Chio et al. 2013).
In summary, evidence for miR-210-mediated regulation of apoptosis in hypoxia is emerging 
for various cell types. However, it is still premature to state that this miRNA represents a 
major protector against hypoxia-induced cell death.
10.3.7 miR-210 Effects on the Cell Cycle
In many cell types, extended exposure to hypoxia leads to downregulation of a large number 
of cell cycle genes, including cyclins and other positive regulators of cell cycle transition 
(Hammer et al. 2007), while other cells tend to proliferate better under low oxygen 
conditions (Krick et al. 2005). One of the better-characterized miR-210 targets that belong to 
cell cycle control is E2F3, a promoter of G 1/S transition (Lees et al. 1993; Leone et al. 
1998). E2F3 was first reported as an miR-210 target in ovarian cancer (Giannakakis et al. 
2008). Later, several independent studies confirmed that E2F3 was an miR-210 target in 
various cell types, including ccRCC (Nakada et al. 2011), keratinocytes and in a murine 
model of ischemic wounds (Biswas et al. 2010), and HEK293 cells (Fasanaro et al. 2009). 
Despite these findings, the relative contribution of E2F3 to tumor cell cycle alterations in a 
hypoxic microenvironment remains largely unknown. In addition to E2F3, fibroblast growth 
factor receptor-like 1 (FGFRL1) also was identified as an miR-210 target involved in cell 
cycle control (Tsuchiya et al. 2011), consistent with our earlier observation that FGFRL1 is 
robustly repressed by miR-210 (Huang et al. 2009). De-repression of FGFRL1 by using anti-
miR-210 accelerates cell cycle progression, whereas overexpression of miR-210 leads to cell 
cycle arrest in the G1/G0 and G2/M phases (Tsuchiya et al. 2011). The effects of miR-210 on 
the cells cycle may, in fact, be significantly broader, including a group of mitosis-related 
genes, such as Plk1, Cdc25B, cyclin F (CCNF), Bub1B, and Fam83D (He et al. 2013). 
Whether all these represent direct targets or more indirect responders downstream of the 
genes discussed above remains unclear.
As is the case with hypoxic cell death, under some circumstances miR-210 may promote cell 
cycle progression, for example, by downregulating MNT (Zhang et al. 2009), a member of 
the Myc/MAX/MAD network with a basic-Helix-Loop-Helix-zipper domain. MNT functions 
as an antagonist of c-Myc and represses Myc target genes by binding the E box DNA 
sequence (CANNTG) after forming heterodimers with MAX (Hurlin et al. 1997; Meroni et 
al. 1997). As HIF-1 regulates cell proliferation and metabolism in part by interacting with c-
Myc (Gordan et al. 2007), miR-210 may fine-tune the latter under hypoxic conditions to 
regulate cell cycle progression.
10.3.8 miR-210 as a Candidate Cancer Biomarker
Past studies have demonstrated that miRNAs are frequently dysregulated in human cancers 
(Ventura and Jacks 2009). Tumor-specific miRNA expression signatures can distinguish 
between normal and malignant tissues as well as classify cancer subtypes (Garzon et al. 
2009). When used to classify poorly differentiated tumors, miRNA expression profiling 
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outperformed mRNA expression profiling (Lu et al. 2005), pointing toward considerable 
potential as a biomarkers. Expression of miR-210 has been associated with poor clinical 
outcome in soft-tissue sarcoma, breast, head and neck, and pancreatic tumors (Camps et al. 
2008; Foekens et al. 2008; Greither et al. 2009; Gee et al. 2010; Greither et al. 2011; Rothe 
et al. 2011; Hong et al. 2012; Toyama et al. 2012). However, whether high miR-210 only 
serves as an indicator of tumor hypoxia or actively promotes a more aggressive disease 
remains unclear (Huang et al. 2010).
The status of miR-210 expression in tumors may have therapeutic implications. Preliminary 
in vitro evidence was provided by Chen et al. (2010), who reported that overexpressing 
miR-210 rendered cells significantly more susceptible to killing by 3-bromo-pyruvate, an 
inhibitor of the glycolytic pathway. Molecules of this class, such as 2-deoxyglucose and 
dichloroacetate, have been considered promising therapeutic agents; however, they have yet 
to fulfill their promise in clinical settings. Therefore, miR-210 may help identify subsets of 
patients who can benefit from such agents in the future.
Recent publications report that miRNAs are exceptionally stable and can be readily detected 
in the systemic circulation and other body fluids of healthy subjects and patients with 
malignant diseases (Chen et al. 2008; Gilad et al. 2008; Lawrie et al. 2008; Mitchell et al. 
2008; Taylor and Gercel-Taylor 2008; Weber et al. 2010). It has been suggested that the 
high stability of miRNAs may be partially attributed to the exosomal miRNA packaging 
(Valadi et al. 2007). The release of exosomes into the extracellular environment provides an 
opportunity to use exosome components in body fluids as a proxy to monitor molecular 
events occurring in tumor cells (Iguchi et al. 2010). Pilot studies assessing the use of 
circulating miRNAs as cancer biomarkers have attracted broad interest in the field and to 
date at least 79 miRNAs have been reported as plasma or serum biomarker candidates for 
solid and hematologic tumors (Allegra et al. 2012). miR-210 was found to be increased in 
the serum of patients with diffuse large B-cell lymphoma (Lawrie et al. 2008), ccRCC (Zhao 
et al. 2013), and pancreatic cancer (Wang et al. 2009; Ho et al. 2010). It is interesting that 
hypoxia has been demonstrated to promote the release of exosomes from cultured breast 
cancer cells (King et al. 2012); therefore, one can speculate that the elevated levels of 
circulating miR-210 may directly reflect the hypoxic state of tumor cells.
Circulating miR-210 levels were also correlated with sensitivity to trastuzumab (a human 
epidermal growth factor receptor 2 monoclonal antibody), tumor presence, and lymph node 
metastases in patients with breast cancer (Jung et al. 2012). This provides proof of the 
concept that plasma miR-210 may also be used to monitor response to anticancer therapies 
(Cortez et al. 2011).
10.3.9 miR-210: A Viable Cancer Therapeutic Target?
Recent development of anti-miRNA agents such as locked nucleic acids or peptide nucleic 
acids represent significant steps for the therapeutic targeting of miRNAs in vivo (Stenvang 
et al. 2008; Lanford et al. 2010; Fabbri et al. 2011a, b; Gambari et al. 2011; Iorio and Croce 
2012). It is conceivable that inactivation of miRNAs involved in hypoxic adaptation, in 
combination with other anticancer agents, may be a viable strategy to target a tumor 
compartment that poses significant therapeutic challenges. At present, efficient delivery of 
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miRNA-related reagents to solid tumors, and in particular to poorly perfused areas, remains 
a significant hurdle. However, rapid advances in nanoparticle-based nucleic acid delivery 
(Tabernero et al. 2013) are providing realistic expectations that such limitations eventually 
will be overcome.
10.4 Concluding Remarks
On the basis of the experimental evidence summarized in this chapter, miR-210 plays 
complex roles in the cellular responses to hypoxia and in cancer biology. Given the diversity 
of genes that seem to respond as bona fide miR-210 targets – some with opposing effects on 
specific cellular functions – a simple and universal model of miR-210 function will be 
challenging to develop using exclusively in vitro approaches. Answering some of the key 
questions regarding miR-210 functions will require data from more sophisticated systems 
such as genetic inactivation of the corresponding locus in animal models.
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Schematic view of microRNA (miRNA) biogenesis and action. RNA polymerase II (Pol II) 
transcribes genes that encode miRNAs into primary miRNAs, which usually have a 5′ cap 
structure and a 3′ poly(A) tail as protein-coding messenger RNAs (mRNAs). The pri-
miRNA is first processed in the nucleus by the microprocessor by two partners, Pasha and 
Drosha, into precursor miRNAs (pre-miRNAs) that are approximately 70 nucleotides in 
length and have a stem-loop structure. The pre-miRNA is then exported into cytoplasm and 
further processed by a type III RNA endonuclease Dicer to generate a mature miRNA 
duplex (~22 nucleotides in length). The sense strand of the miRNA duplex is then loaded 
into the RNA-induced silencing complex (RISC), whereas the complementary “star” strand 
(*) of the miRNA duplex is degraded. The RISC regulates gene expression through the 
inhibition of RNA translation or degradation of target mRNA by base pairing the “seed 
region” of an miRNA to the 3′ untranslated region of its target mRNA. This figure is 
modified from Huang et al. (2010)
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Experimentally identified micro RNA target genes implicated in cancer biology. Genes that 
have been experimentally identified as miR-210 targets can be classified into five major 
functional categories: mitochondrial metabolism, cell cycle control, angiogenesis, apoptosis, 
and DNA damage repair, indicating a complex functional network regulated by miR-210 in 
the hypoxic microenvironment in which tumor cells reside
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